Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

50.38
+0.77001.55%
Volume:7.56M
Turnover:378.59M
Market Cap:102.53B
PE:18.87
High:50.49
Open:50.15
Low:49.68
Close:49.61
Loading ...

What to Watch in the Day Ahead - Thursday, April 24

Reuters
·
24 Apr

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

Zacks
·
24 Apr

Bristol-Myers Squibb Price Target Maintained With a $55.00/Share by Cantor Fitzgerald

Dow Jones
·
23 Apr

Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook -- Barrons.com

Dow Jones
·
23 Apr

Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow?

Insider Monkey
·
23 Apr

Bristol Myers Squibb Shares Down 2% After Cobenfy Fails in Key Study as Add-on Treatment for Schizophrenia

THOMSON REUTERS
·
23 Apr

BUZZ-Street View: Bristol Myers blows uptake opportunity with Cobenfy trial failure

Reuters
·
23 Apr

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Zacks
·
23 Apr

Bristol-Myers Squibb Is Maintained at Buy by Jefferies

Dow Jones
·
23 Apr

Pre-Bell | Nasdaq Futures up 3%; Tesla, SAP Jump 8%; Nvidia, Palantir Rise 6%; Boeing up 5%

Tiger Newspress
·
23 Apr

Bristol Myers Stock Falls After Drug Trial Setback. Why 1 Analyst Isn't Worried. -- Barrons.com

Dow Jones
·
23 Apr

Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect

StockStory
·
23 Apr

Deutsche Bank Adjusts Bristol-Myers Squibb Price Target to $51 From $53, Maintains Hold Rating

MT Newswires Live
·
23 Apr

Bristol Myers Squibb Shares Dip 2.7% Premarket After Cobenfy Fails in Key Study as Add-on Treatment for Schizophrenia

THOMSON REUTERS
·
23 Apr

Bristol-Myers Squibb Co : Jefferies Cuts Target Price to $68.00 From $70.00

THOMSON REUTERS
·
23 Apr

Aurobindo Pharma Arm Gets US FDA Final Nod for Dasatinib Tablets, Shares Up 3%

MT Newswires Live
·
23 Apr

U.S. RESEARCH ROUNDUP-3M, Intuit, Starbucks

Reuters
·
23 Apr

Bristol-Myers Squibb Co : Leerink Partners Cuts Target Price to $55 From $68

THOMSON REUTERS
·
23 Apr

Bristol-Myers Adjunctive Treatment for Schizophrenia Fails to Meet Primary Endpoint

MT Newswires Live
·
23 Apr

Bristol Myers Squibb's Schizophrenia Treatment Falls Flat

Dow Jones
·
23 Apr